Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Bertilsson, L' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 102 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Wennerholm, A; Johansson, I; Hidestrand, M; Bertilsson, L; Gustafsson, LL; IngelmanSundberg, M
      Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity (vol 11, pg 417, 2001)

      PHARMACOGENETICS
    2. Wennerholm, A; Johansson, I; Hidestrand, M; Bertilsson, L; Gustafsson, LL; Ingelman-Sundberg, M
      Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity

      PHARMACOGENETICS
    3. Roh, HK; Chung, JY; Oh, DY; Park, CS; Svensson, JO; Dahl, ML; Bertilsson, L
      Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Hartter, S; Morita, S; Bodin, K; Ursing, C; Tybring, G; Bertilsson, L
      Determination of exogenous melatonin and its 6-hydroxy metabolite in humanplasma by liquid chromatography-mass spectrometry

      THERAPEUTIC DRUG MONITORING
    5. Alvan, G; Bertilsson, L; Dahl, ML; Ingelman-Sundberg, M; Sjoqvist, F
      Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation

      DRUG METABOLISM AND DISPOSITION
    6. Laine, K; Anttila, M; Nyman, L; Wahlberg, A; Bertilsson, L
      CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    7. Bodin, K; Bretillon, L; Aden, Y; Bertilsson, L; Broome, U; Einarsson, C; Diczfalusy, U
      Antiepileptic drugs increase plasma levels of 4 beta-hydroxycholesterol inhumans - Evidence for involvement of cytochrome P450 3A4

      JOURNAL OF BIOLOGICAL CHEMISTRY
    8. Laine, K; Tybring, G; Hartter, S; Andersson, K; Svensson, JO; Widen, J; Bertilsson, L
      Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    9. Hartter, S; Ursing, C; Morita, S; Tybring, G; von Bahr, C; Christensen, M; Rojdmark, S; Bertilsson, L
      Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    10. Bertilsson, L; Kalow, W
      Interethnic differences in drug disposition and effects

      INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM
    11. Dalen, P; Dahl, ML; Andersson, K; Bertilsson, L
      Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Sagar, M; Bertilsson, L; Stridsberg, M; Kjellin, A; Mardh, S; Seensalu, R
      Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    13. Carrillo, JA; Christensen, M; Ramos, SI; Alm, C; Dahl, ML; Benitez, J; Bertilsson, L
      Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

      THERAPEUTIC DRUG MONITORING
    14. Scordo, MG; Spina, E; Romeo, P; Dahl, ML; Bertilsson, L; Johansson, I; Sjoqvist, F
      CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    15. von Bahr, C; Ursing, C; Yasui, N; Tybring, G; Bertilsson, L; Rojdmark, S
      Fluvoxamine but not citalopram increases serum melatonin in healthy subjects - an indication that cytochrome P-450 CYP1A2 and CYP2C19 hydroxylate melatonin

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    16. Sagar, M; Tybring, G; Dahl, ML; Bertilsson, L; Seensalu, R
      Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism

      GASTROENTEROLOGY
    17. Laine, K; Tybring, G; Bertilsson, L
      No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    18. Herrlin, K; Massele, AY; Rimoy, G; Alm, C; Rais, M; Ericsson, O; Bertilsson, L; Gustafsson, LL
      Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    19. Lidberg, L; Belfrage, H; Bertilsson, L; Evenden, MM; Asberg, M
      Suicide attempts and impulse control disorder are related to low cerebrospinal fluid 5-HIAA in mentally disordered violent offenders

      ACTA PSYCHIATRICA SCANDINAVICA
    20. Dalen, P; Dahl, ML; Eichelbaum, M; Bertilsson, L; Wilkinson, GR
      Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

      PHARMACOGENETICS
    21. Wennerholm, A; Johansson, I; Massele, AY; Jande, M; Alm, C; Aden-Abdi, Y; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L; Gustafsson, LL
      Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype

      PHARMACOGENETICS
    22. Kaneko, A; Lum, JK; Yaviong, J; Takahashi, N; Ishizaki, T; Bertilsson, L; Kobayakawa, T; Bjorkman, A
      High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands

      PHARMACOGENETICS
    23. Bernal, ML; Sinues, B; Johansson, I; McLellan, RA; Wennerholm, A; Dahl, ML; Ingelman-Sundberg, M; Bertilsson, L
      Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

      PHARMACOGENETICS
    24. Svensson, JO; Bertilsson, L
      Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxydebrisoquine in urine for CYP2D6 phenotyping

      PHARMACOGENETICS
    25. Mihara, K; Svensson, USH; Tybring, G; Hai, TN; Bertilsson, L; Ashton, M
      Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    26. Bertilsson, L; Potje-Kamloth, K; Liess, HD; Liedberg, B
      On the adsorption of dimethyl methylphosphonate on self-assembled alkanethiolate monolayers: Influence of humidity

      LANGMUIR
    27. Brynne, N; Svanstrom, C; Aberg-Wistedt, A; Hallen, B; Bertilsson, L
      Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    28. Brynne, N; Forslund, C; Hallen, B; Gustafsson, LL; Bertilsson, L
      Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    29. Brynne, N; Bottiger, Y; Hallen, B; Bertilsson, L
      Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    30. Shimoda, K; Jerling, M; Bottiger, Y; Yasuda, S; Morita, S; Bertilsson, L
      Pronounced differences in the disposition of clomipramine between Japaneseand Swedish patients

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    31. Sagar, M; Janczewska, I; Ljungdahl, A; Bertilsson, L; Seensalu, R
      Effect of CYP2C19 polymorphism on serum levels of vitamin B-12 in patientson long-term omeprazole treatment

      ALIMENTARY PHARMACOLOGY & THERAPEUTICS
    32. Persson, I; Johansson, I; Lou, YC; Yue, QY; Duan, LS; Bertilsson, L; Ingelman-Sundberg, M
      Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lungcancer patients

      INTERNATIONAL JOURNAL OF CANCER
    33. Mirghani, RA; Hellgren, U; Westerberg, PA; Ericsson, O; Bertilsson, L; Gustafsson, LL
      The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quininein vivo

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    34. Linner, L; Arborelius, L; Nomikos, GG; Bertilsson, L; Svensson, TH
      Locus coeruleus neuronal activity and noradrenaline availability in the frontal cortex of rats chronically treated with imipramine effect of alpha(2)-adrenoceptor blockade

      BIOLOGICAL PSYCHIATRY
    35. BERTILSSON L; POTJEKAMLOTH K; LIESS HD; ENGQUIST I; LIEDBERG B
      ADSORPTION OF DIMETHYL METHYLPHOSPHONATE ON SELF-ASSEMBLED ALKANETHIOLATE MONOLAYERS

      JOURNAL OF PHYSICAL CHEMISTRY B
    36. EIERMANN B; EDLUND PO; TJERNBERG A; DALEN P; DAHL ML; BERTILSSON L
      1-HYDROXYLATION AND 3-HYDROXYLATION, IN ADDITION TO 4-HYDROXYLATION, OF DEBRISOQUINE ARE CATALYZED BY CYTOCHROME-P450 2D6 IN HUMANS

      Drug metabolism and disposition
    37. SAGAR M; SEENSALU R; TYBRING G; DAHL ML; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED WITH OMEPRAZOLE IN PATIENTSWITH ACID-RELATED DISORDERS WITH AND WITHOUT HELICOBACTER-PYLORI INFECTION

      Scandinavian journal of gastroenterology
    38. BERTILSSON L
      INTERETHNIC DIFFERENCES IN THE CYP2D6 POLYMORPHISM WITH EMPHASIS ON GENE DUPLICATION AMPLIFICATION/

      Naunyn-Schmiedeberg's archives of pharmacology
    39. SAGAR M; TYBRING G; DAHL ML; BERTILSSON L; SEENSALU R
      THE EFFECT OF OMEPRAZOLE ON INTRAGASTRIC PH AND GASTRIN-LEVELS IS DETERMINED BY THE CYP2C19 POLYMORPHISM MORE THAN BY HELICOBACTER-PYLORI INFECTION IN PATIENTS WITH ACID-RELATED DISEASE

      Gastroenterology
    40. ARLANDER E; EKSTROM G; ALM C; CARRILLO JA; BIELENSTEIN M; BOTTIGER Y; BERTILSSON L; GUSTAFSSON LL
      METABOLISM OF ROPIVACAINE IN HUMANS IS MEDIATED BY CYP1A2 AND TO A MINOR EXTENT BY CYP3A4 - AN INTERACTION STUDY WITH FLUVOXAMINE AND KETOCONAZOLE AS IN-VIVO INHIBITORS

      Clinical pharmacology and therapeutics
    41. YUE QY; ZHONG ZH; TYBRING G; DALEN P; DAHL ML; BERTILSSON L; SJOQVIST F
      PHARMACOKINETICS OF NORTRIPTYLINE AND ITS 10-HYDROXY METABOLITE IN CHINESE SUBJECTS OF DIFFERENT CYP2D6 GENOTYPES

      Clinical pharmacology and therapeutics
    42. HERRLIN K; MASSELE AY; JANDE M; ALM C; TYBRING G; ABDI YA; WENNERHOLM A; JOHANSSON I; DAHL ML; BERTILSSON L; GUSTAFSSON LL
      BANTU TANZANIANS HAVE A DECREASED CAPACITY TO METABOLIZE OMEPRAZOLE AND MEPHENYTOIN IN RELATION TO THEIR CYP2C19 GENOTYPE

      Clinical pharmacology and therapeutics
    43. SCHEININ H; ANTTILA M; DAHL ML; KARNANI H; NYMAN L; TAAVITSAINEN P; PELKONEN O; BERTILSSON L
      CYP2D6 POLYMORPHISM IS NOT CRUCIAL FOR THE DISPOSITION OF SELEGILINE

      Clinical pharmacology and therapeutics
    44. SVENSSON USH; ASHTON M; HAI TN; BERTILSSON L; HUONG DX; VANHUONG N; NIEU NT; SY ND; LYKKESFELDT J; CONG LD
      ARTEMISININ INDUCES OMEPRAZOLE METABOLISM IN HUMAN-BEINGS

      Clinical pharmacology and therapeutics
    45. BRYNNE N; DALEN P; ALVAN G; BERTILSSON L; GABRIELSSON J
      INFLUENCE OF CYP2D6 POLYMORPHISM ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF TOLTERODINE

      Clinical pharmacology and therapeutics
    46. DALEN P; DAHL ML; RUIZ MLB; NORDIN J; BERTILSSON L
      10-HYDROXYLATION OF NORTRIPTYLINE IN WHITE PERSONS WITH 0-FUNCTIONAL,1-FUNCTIONAL, 2-FUNCTIONAL, 3-FUNCTIONAL, AND 13-FUNCTIONAL C-UPSILON-P2D6 GENES

      Clinical pharmacology and therapeutics
    47. BERTILSSON L; ENGQUIST I; LIEDBERG B
      INTERACTION OF DIMETHYL METHYLPHOSPHONATE WITH ALKANETHIOLATE MONOLAYERS STUDIED BY TEMPERATURE-PROGRAMMED DESORPTION AND INFRARED-SPECTROSCOPY

      JOURNAL OF PHYSICAL CHEMISTRY B
    48. SHIMODA K; YASUDA S; MORITA S; SHIBASAKI M; SOMEYA T; BERTILSSON L; TAKAHASHI S
      SIGNIFICANCE OF MONITORING PLASMA-LEVELS OF AMITRIPTYLINE, AND ITS HYDROXYLATED AND DESMETHYLATED METABOLITES IN PREDICTION OF THE CLINICALOUTCOME OF DEPRESSIVE STATE

      PSYCHIATRY AND CLINICAL NEUROSCIENCES
    49. DAHL ML; VOORTMAN G; ALM C; ELWIN CE; DELBRESSINE L; VOS R; BOGAARDS JJP; BERTILSSON L
      IN-VITRO AND IN-VIVO STUDIES ON THE DISPOSITION OF MIRTAZAPINE IN HUMANS

      Clinical drug investigation
    50. TYRING G; NORDIN J; BERGMAN T; BERTILSSON L
      AN S-MEPHENYTOIN CYSTEINE CONJUGATE IDENTIFIED IN URINE OF EXTENSIVE BUT NOT OF POOR METABOLIZERS OF S-MEPHENYTOIN

      Pharmacogenetics
    51. BERTILSSON L; BUTT HJ; NELLES G; SCHLERETH DD
      CIBACRON-BLUE F3G-A ANCHORED MONOLAYERS WITH BIOSPECIFIC AFFINITY FORNAD(H)-DEPENDENT LACTATE-DEHYDROGENASE - CHARACTERIZATION BY FTIR-SPECTROSCOPY AND ATOMIC-FORCE MICROSCOPY

      Biosensors & bioelectronics
    52. EIERMANN B; ENGEL G; JOHANSSON I; ZANGER UM; BERTILSSON L
      THE INVOLVEMENT OF CYP1A2 AND CYP3A4 IN THE METABOLISM OF CLOZAPINE

      British journal of clinical pharmacology
    53. BERTILSSON L; TYBRING G; WIDEN J; CHANG M; TOMSON T
      CARBAMAZEPINE TREATMENT INDUCES THE CYP3A4 CATALYZED SULFOXIDATION OFOMEPRAZOLE, BUT HAS NO OR LESS EFFECT ON HYDROXYLATION VIA CYP2C19

      British journal of clinical pharmacology
    54. MIHARA K; OTANI K; TYBRING G; DAHL ML; BERTILSSON L; KANEKO S
      THE CYP2D6 GENOTYPE AND PLASMA-CONCENTRATIONS OF MIANSERIN ENANTIOMERS IN RELATION TO THERAPEUTIC RESPONSE TO MIANSERIN IN DEPRESSED JAPANESE PATIENTS

      Journal of clinical psychopharmacology
    55. EIERMANN B; ENGEL G; BERTILSSON L
      CLOZAPINE METABOLISM IN-VITRO IS CATALYZED BY CYP1A2 AND CYP3A4

      Naunyn-Schmiedeberg's archives of pharmacology
    56. SAGAR M; BERTILSSON L; DAHL ML; TYBRING G; SEENSALU R
      INDIVIDUAL METABOLISM OF OMEPRAZOLE IS DETERMINED BY THE GENOTYPE OF THE ENZYME CYP2C19 WITHOUT RELATION TO HELICOBACTER-PYLORI INFECTION

      Gastroenterology
    57. BOTTIGER Y; TYBRING G; GOTHARSON E; BERTILSSON L
      INHIBITION OF THE SULFOXIDATION OF OMEPRAZOLE BY KETOCONAZOLE IN POORAND EXTENSIVE METABOLIZERS OF S-MEPHENYTOIN

      Clinical pharmacology and therapeutics
    58. TYBRING G; BOTTIGER Y; WIDEN J; BERTILSSON L
      ENANTIOSELECTIVE HYDROXYLATION OF OMEPRAZOLE CATALYZED BY CYP2C19 IN SWEDISH WHITE SUBJECTS

      Clinical pharmacology and therapeutics
    59. BERTILSSON L; DAHL ML; TYBRING G
      PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS

      Acta psychiatrica Scandinavica
    60. BERTILSSON L; DAHL ML
      POLYMORPHIC DRUG OXIDATION - RELEVANCE TO THE TREATMENT OF PSYCHIATRIC-DISORDERS

      CNS DRUGS
    61. PERSSON I; AKLILLU E; RODRIGUES F; BERTILSSON L; INGELMANSUNDBERG M
      S-MEPHENYTOIN HYDROXYLATION PHENOTYPE AND CYP2C19 GENOTYPE AMONG ETHIOPIANS

      Pharmacogenetics
    62. ROH HK; DAHL ML; TYBRING G; YAMADA H; CHA YN; BERTILSSON L
      CYP2C19 GENOTYPE AND PHENOTYPE DETERMINED BY OMEPRAZOLE IN A KOREAN POPULATION

      Pharmacogenetics
    63. ROH HK; DAHL ML; JOHANSSON I; INGELMANSUNDBERG M; CHA YN; BERTILSSON L
      DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION PHENOTYPES AND GENOTYPESIN A KOREAN POPULATION

      Pharmacogenetics
    64. BOTTIGER Y; DOSTERT P; BENEDETTI MS; BANI M; FIORENTINI F; CASATI M; POGGESTI I; ALM C; ALVAN G; BERTILSSON L
      INVOLVEMENT OF CYP2D6 BUT NOT CYP2C19 IN NICERGOLINE METABOLISM IN HUMANS

      British journal of clinical pharmacology
    65. MASIMIREMBWA C; PERSSON I; BERTILSSON L; HASLER J; INGELMANSUNDBERG M
      A NOVEL MUTANT VARIANT OF THE CYP2D6 GENE (CYP2D6-ASTERISK-17) COMMONIN A BLACK-AFRICAN POPULATION - ASSOCIATION WITH DIMINISHED DEBRISOQUINE HYDROXYLASE-ACTIVITY

      British journal of clinical pharmacology
    66. BERTILSSON L; POTJEKAMLOTH K; LIESS HD
      MOLECULAR INTERACTION OF DMMP AND WATER-VAPOR WITH MIXED SELF-ASSEMBLED MONOLAYERS STUDIED BY IR SPECTROSCOPY AND SAW DEVICES

      Thin solid films
    67. AKLILLU E; PERSSON I; BERTILSSON L; JOHANSSON I; RODRIGUES F; INGELMANSUNDBERG M
      FREQUENT DISTRIBUTION OF ULTRARAPID METABOLIZERS OF DEBRISOQUINE IN AN ETHIOPIAN POPULATION CARRYING DUPLICATED AND MULTIDUPLICATED FUNCTIONAL CYP2D6 ALLELES

      The Journal of pharmacology and experimental therapeutics
    68. CARRILLO JA; DAHL ML; SVENSSON JO; ALM C; RODRIGUEZ I; BERTILSSON L
      DISPOSITION OF FLUVOXAMINE IN HUMANS IS DETERMINED BY THE POLYMORPHICCYP2D6 AND ALSO BY THE CYP1A2 ACTIVITY

      Clinical pharmacology and therapeutics
    69. JERLING M; DAHL ML; ABERGWISTEDT A; LILJENBERG B; LANDELL NE; BERTILSSON L; SJOQVIST F
      THE CYP2D6 GENOTYPE PREDICTS THE ORAL CLEARANCE OF THE NEUROLEPTIC AGENTS PERPHENAZINE AND ZUCLOPENTHIXOL

      Clinical pharmacology and therapeutics
    70. MEYER UA; AMREIN R; BALANT LP; BERTILSSON L; EICHELBAUM M; GUENTERT TW; HENAUER S; JACKSON P; LAUX G; MIKKELSEN H; PECK C; POLLOCK BG; PRIEST R; SJOQVIST F; DELINISTULA A
      ANTIDEPRESSANTS AND DRUG-METABOLIZING-ENZYMES - EXPERT GROUP-REPORT

      Acta psychiatrica Scandinavica
    71. DAHL ML; BERTILSSON L; NORDIN C
      STEADY-STATE PLASMA-LEVELS OF NORTRIPTYLINE AND ITS 1.0-HYDROXY METABOLITE - RELATIONSHIP TO THE CYP2D6 GENOTYPE

      Psychopharmacology
    72. BOTTIGER Y; BERTILSSON L
      NO EFFECT ON PLASMA CARBAMAZEPINE CONCENTRATION WITH CONCOMITANT OMEPRAZOLE TREATMENT

      Clinical drug investigation
    73. CHANG M; DAHL ML; TYBRING G; GOTHARSON E; BERTILSSON L
      USE OF OMEPRAZOLE AS A PROBE DRUG FOR CYP2C19 PHENOTYPE IN SWEDISH CAUCASIANS - COMPARISON WITH S-MEPHENYTOIN HYDROXYLATION PHENOTYPE AND CYP2C19 GENOTYPE

      Pharmacogenetics
    74. DAHL ML; YUE QY; ROH HK; JOHANSSON I; SAWE J; SJOQVIST F; BERTILSSON L
      GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS

      Pharmacogenetics
    75. YUE QY; SVENSSON JO; SAWE J; BERTILSSON L
      CODEINE METABOLISM IN 3 ORIENTAL POPULATIONS - A PILOT-STUDY IN CHINESE, JAPANESE AND KOREANS

      Pharmacogenetics
    76. BERTILSSON L
      GEOGRAPHICAL INTERRACIAL DIFFERENCES IN POLYMORPHIC DRUG OXIDATION - CURRENT STATE OF KNOWLEDGE OF CYTOCHROMES P450 (CYP) 2D6 AND 2C19

      Clinical pharmacokinetics
    77. NORDIN C; BERTILSSON L
      ACTIVE HYDROXYMETABOLITES OF ANTIDEPRESSANTS - EMPHASIS ON E-10-HYDROXY-NORTRIPTYLINE

      Clinical pharmacokinetics
    78. CHANG M; TYBRING G; DAHL ML; GOTHARSON E; SAGAR M; SEENSALU R; BERTILSSON L
      INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19

      British journal of clinical pharmacology
    79. CARRILLO JA; JERLING M; BERTILSSON L
      INTERACTION BETWEEN CAFFEINE AND CLOZAPINE - COMMENT

      Journal of clinical psychopharmacology
    80. TYBRING G; OTANI K; KANEKO S; MIHARA K; FUKUSHIMA Y; BERTILSSON L
      ENANTIOSELECTIVE DETERMINATION OF MIANSERIN AND ITS DESMETHYL METABOLITE IN PLASMA DURING TREATMENT OF DEPRESSED JAPANESE PATIENTS

      Therapeutic drug monitoring
    81. DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
      ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS

      The Journal of pharmacology and experimental therapeutics
    82. MASIMIREMBWA C; BERTILSSON L; JOHANSSON I; HASLER JA; INGELMANSUNDBERG M
      PHENOTYPING AND GENOTYPING OF S-MEPHENYTOIN HYDROXYLASE (CYTOCHROME-P450 2C19) IN A SHONA POPULATION OF ZIMBABWE

      Clinical pharmacology and therapeutics
    83. INABA T; NEBERT DW; BURCHELL B; WATKINS PB; GOLDSTEIN JA; BERTILSSON L; TUCKER GT
      PHARMACOGENETICS IN CLINICAL-PHARMACOLOGY AND TOXICOLOGY

      Canadian journal of physiology and pharmacology
    84. NYBERG S; FARDE L; HALLDIN C; DAHL ML; BERTILSSON L
      D-2 DOPAMINE-RECEPTOR OCCUPANCY DURING LOW-DOSE TREATMENT WITH HALOPERIDOL DECANOATE

      The American journal of psychiatry
    85. NYBERG S; HALLDIN C; BERTILSSON L; FARDE L
      D2 OCCUPANCY IN SCHIZOPHRENIC-PATIENTS ON DEPOT NEUROLEPTICS

      Schizophrenia research
    86. NORDSTROM P; SAMUELSSON M; ASBERG M; TRASKMANBENDZ L; ABERGWISTEDT A; NORDIN C; BERTILSSON L
      CSF 5-HIAA PREDICTS SUICIDE RISK AFTER ATTEMPTED-SUICIDE

      Suicide & life-threatening behavior
    87. BERTILSSON L; CARRILLO JA; DAHL ML; LLERENA A; ALM C; BONDESSON U; LINDSTROM L; DELARUBIA IR; RAMOS S; BENITEZ J
      CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST

      British journal of clinical pharmacology
    88. DAHL ML; LLERENA A; BONDESSON U; LINDSTROM L; BERTILSSON L
      DISPOSITION OF CLOZAPINE IN MAN - LACK OF ASSOCIATION WITH DEBRISOQUINE AND S-MEPHENYTOIN HYDROXYLATION POLYMORPHISMS

      British journal of clinical pharmacology
    89. TORESSON G; BRODIN E; DELASCARRERAS C; NORDIN C; ZACHAU AC; BERTILSSON L
      QUANTITATION OF N-TERMINALLY EXTENDED TACHYKININS IN CEREBROSPINAL-FLUID FROM HEALTHY-SUBJECTS

      Regulatory peptides
    90. JERLING M; LINDSTROM L; BONDESSON U; BERTILSSON L
      FLUVOXAMINE INHIBITION AND CARBAMAZEPINE INDUCTION OF THE METABOLISM OF CLOZAPINE - EVIDENCE FROM A THERAPEUTIC DRUG-MONITORING SERVICE

      Therapeutic drug monitoring
    91. ISHIZAKI T; SOHN DR; KOBAYASHI K; CHIBA K; LEE KH; SHIN SG; ANDERSSON T; REGARDH CG; LOU YC; ZHANG Y; DAHL ML; BERTILSSON L
      INTERETHNIC DIFFERENCES IN OMEPRAZOLE METABOLISM IN THE 2 S-MEPHENYTOIN HYDROXYLATION PHENOTYPES STUDIED IN CAUCASIANS AND ORIENTALS

      Therapeutic drug monitoring
    92. JERLING M; BERTILSSON L; SJOQVIST F
      THE USE OF THERAPEUTIC DRUG-MONITORING DATA TO DOCUMENT KINETIC DRUG-INTERACTIONS - AN EXAMPLE WITH AMITRIPTYLINE AND NORTRIPTYLINE

      Therapeutic drug monitoring
    93. JOHANSSON I; OSCARSON M; YUE QY; BERTILSSON L; SJOQVIST F; INGELMANSUNDBERG M
      GENETIC-ANALYSIS OF THE CHINESE CYTOCHROME P4502D LOCUS - CHARACTERIZATION OF VARIANT CYP2D6 GENES PRESENT IN SUBJECTS WITH DIMINISHED CAPACITY FOR DEBRISOQUINE HYDROXYLATION

      Molecular pharmacology
    94. DAHL ML; TYBRING G; ELWIN CE; ALM C; ANDREASSON K; GYLLENPALM M; BERTILSSON L
      STEREOSELECTIVE DISPOSITION OF MIANSERIN IS RELATED TO DEBRISOQUIN HYDROXYLATION POLYMORPHISM

      Clinical pharmacology and therapeutics
    95. DAHL ML; BERTILSSON L
      GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN

      Pharmacogenetics
    96. BERTILSSON L; MEESE CO; YUE QY; DAHL ML; INGELMANSUNDBERG M; JOHANSSON I; SAWE J; EICHELBAUM M
      QUINIDINE INHIBITION OF DEBRISOQUINE S(-4-HYDROXYLATIONS AND 7-HYDROXYLATIONS IN CHINESE OF DIFFERENT CYP2D6 GENOTYPES())

      Pharmacogenetics
    97. LLERENA A; VALDIVIELSO MJ; BENITEZ J; BERTILSSON L
      REPRODUCIBILITY OVER TIME OF MEPHENYTOIN AND DEBRISOQUINE HYDROXYLATION PHENOTYPES

      Pharmacology & toxicology
    98. TORESSON G; BRODIN E; BERTILSSON L
      N-TERMINALLY EXTENDED TACHYKININS IN HUMAN CEREBROSPINAL-FLUID

      Regulatory peptides
    99. REVIRIEGO J; BERTILSSON L; CARRILLO JA; LLERENA A; VALDIVIELSO MJ; BENITEZ J
      FREQUENCY OF S-MEPHENYTOIN HYDROXYLATION DEFICIENCY IN 373 SPANISH SUBJECTS COMPARED TO OTHER CAUCASIAN POPULATIONS

      European Journal of Clinical Pharmacology
    100. JOHANSSON I; LUNDQVIST E; BERTILSSON L; DAHL ML; SJOQVIST F; INGELMANSUNDBERG M
      INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE

      Proceedings of the National Academy of Sciences of the United Statesof America


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 14:55:56